{"id":58897,"date":"2024-02-28T05:33:05","date_gmt":"2024-02-28T05:33:05","guid":{"rendered":"https:\/\/medsname.com\/pramirol\/"},"modified":"2026-05-01T10:49:14","modified_gmt":"2026-05-01T10:49:14","slug":"pramirol","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/pramirol\/","title":{"rendered":"Pramirol"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer<\/h3>\n

Pramirol<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03bf\u03c5 \u03c3\u03c4\u03cc\u03bc\u03b1\u03c4\u03bf\u03c2 pramipexole<\/strong> (1 mg or 1.5 mg) tablet \u2014 a non-ergot dopamine agonist<\/strong> \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03b5\u03af\u03c4\u03b1\u03b9 \u03b3\u03b9\u03b1 \u03c4\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 Parkinson disease<\/strong> \u03ba\u03b1\u03b9 moderate-to-severe restless legs syndrome (RLS)<\/strong>. It directly stimulates dopamine D2\/D3 receptors in the brain, partially substituting for the dopamine that is no longer being made. Pramipexole is excreted almost entirely unchanged by the kidneys — renal dosing is essential. It has the highest D3:D2 selectivity of all clinical dopamine agonists, which may explain its anti-depressant effect (FDA-recognised for depressive symptoms in Parkinson disease). Critical safety signals:<\/strong> impulse-control disorders<\/em> (gambling, hypersexuality, binge eating, compulsive shopping), sudden-onset sleep<\/em> (sleep attacks while driving), and orthostatic hypotension. Dose must be titrated up slowly and tapered down slowly — never stopped abruptly.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n

What Is Pramirol?<\/h2>\n

Pramirol is an oral tablet containing pramipexole 1 mg or 1.5 mg<\/strong>. pramipexole is a non-ergot dopamine D2\/D3 receptor agonist<\/strong>, originally introduced as Mirapex \/ Mirapexin \/ Sifrol<\/strong>. Pramirol is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n

Pramipexole is one of the two most widely used non-ergot dopamine agonists (the other is ropinirole). It is suitable as monotherapy in early Parkinson disease — particularly in younger patients where delaying levodopa is desirable — and as adjunct in advanced disease. Distinctively among Parkinson medications, pramipexole has documented anti-depressant activity and is sometimes specifically chosen in PD patients who have prominent depressive symptoms. It is also licensed for moderate-to-severe restless legs syndrome.<\/p>\n

How Does Pramirol (pramipexole) Work?<\/h2>\n

Pramipexole directly stimulates dopamine D2 and D3 receptors, with markedly higher affinity for D3 than D2 — the highest D3 selectivity of any clinically used dopamine agonist. D3 receptors are concentrated in the limbic system, which may explain the documented anti-depressant effect seen with pramipexole that is less prominent with other agonists. It does not affect serotonin 5-HT2B receptors, so does not cause cardiac valve fibrosis. Excretion is almost entirely renal — the kidney handles >90% unchanged.<\/p>\n

Who Is Pramirol For?<\/h2>\n

Pramirol is appropriate for adults with Parkinson disease (monotherapy in early disease, adjunct to levodopa in advanced disease) and for moderate-to-severe restless legs syndrome unresponsive to non-pharmacological measures and iron repletion. It is sometimes specifically chosen in Parkinson patients with prominent depressive symptoms because of its independent anti-depressant action. Younger PD patients (under 65) often benefit from starting with a dopamine agonist before levodopa, to delay levodopa-induced dyskinesia.<\/p>\n

Dosing and Titration<\/h2>\n

Dopamine agonist therapy must<\/strong> be titrated upwards over weeks to avoid intolerable nausea, postural hypotension and somnolence. The dose schedule below is a typical starting framework — your neurologist will tailor it to your response.<\/p>\n\n\n\n\n\n\n\n\n\n
\u0395\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03b1<\/th>\nPramipexole “salt” dose for Parkinson disease<\/th>\nFor RLS<\/th>\n<\/tr>\n<\/thead>\n
1<\/td>\n0.125 mg three times daily (0.375 mg\/day)<\/td>\n0.125 mg 2–3 hours before bedtime<\/td>\n<\/tr>\n
2<\/td>\n0.25 mg three times daily (0.75 mg\/day)<\/td>\n0.25 mg at bedtime<\/td>\n<\/tr>\n
3<\/td>\n0.5 mg three times daily (1.5 mg\/day)<\/td>\n0.5 mg at bedtime<\/td>\n<\/tr>\n
\u03a3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7<\/td>\n1.5–4.5 mg\/day in 3 divided doses<\/td>\n0.125–0.75 mg at bedtime<\/td>\n<\/tr>\n
Renal dosing (CrCl 35–50)<\/td>\nReduce frequency — 0.125 mg twice daily start<\/td>\nCrCl < 20 ml\/min: avoid<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Pramipexole is also available as a once-daily prolonged-release tablet (Mirapex ER) for Parkinson disease — not in this Pramirol presentation. Renal function dictates dosing strongly: in CrCl 35–50 ml\/min start at 0.125 mg twice daily; in CrCl 15–35 start at 0.125 mg once daily; in CrCl < 15 ml\/min avoid.<\/p>\n

⚠ Impulse-control disorders — the warning every patient (and partner) needs to hear<\/strong> Up to 14–17%<\/strong> of patients on dopamine agonists develop one or more impulse-control disorders<\/em>: pathological gambling, compulsive shopping, hypersexuality, binge eating, or punding (repetitive purposeless behaviour). The risk is dose-dependent and is highest with non-ergot agonists. Patients are often unaware of the change — partners and family members may notice it first. If you or someone close to you observes any new compulsive behaviour, contact your neurologist promptly.<\/strong> Dose reduction or discontinuation usually reverses the behaviour within weeks.<\/div>\n
⚠ Sudden-onset sleep (“sleep attacks”)<\/strong> All non-ergot dopamine agonists can cause sudden, irresistible episodes of sleep without warning — including while driving, eating, or in conversation. This is more common in the first months of treatment, at higher doses, and when combined with levodopa. Until you have been on a stable dose for at least 2 weeks and know how you respond, do not drive, operate machinery, or engage in activities where falling asleep would be dangerous.<\/strong><\/div>\n

\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u03c0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n

Common (>10%):<\/strong> nausea, dizziness, somnolence, postural hypotension, peripheral oedema (ankle swelling), constipation, hallucinations (visual more than auditory), dyskinesia (when combined with levodopa).<\/p>\n

\u039b\u03b9\u03b3\u03cc\u03c4\u03b5\u03c1\u03bf \u03c3\u03c5\u03c7\u03bd\u03ad\u03c2 \u03b1\u03bb\u03bb\u03ac \u03c3\u03bf\u03b2\u03b1\u03c1\u03ad\u03c2:<\/strong> sudden-onset sleep, impulse-control disorders, livedo reticularis (mottled skin pattern), vivid dreams, leg oedema, syncope, dyskinesia, hallucinations, paranoia.<\/p>\n

\u03a3\u03c0\u03ac\u03bd\u03b9\u03b1:<\/strong> dopamine agonist withdrawal syndrome (DAWS) on rapid taper — depression, anxiety, panic, fatigue, drug craving, autonomic instability. This is the reason agonists must be tapered slowly.<\/p>\n

\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n